News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license a... AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. Show more
Ask ADVFN Intelligence (AI)
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.9 | -23.0769230769 | 3.9 | 3.9 | 3 | 9186 | 3.54549835 | CS |
| 4 | -0.84 | -21.875 | 3.84 | 3.99 | 3 | 4979 | 3.62201706 | CS |
| 12 | -3.3 | -52.380952381 | 6.3 | 6.3 | 3 | 7758 | 3.92643757 | CS |
| 26 | -3.215 | -51.729686243 | 6.215 | 6.7738 | 3 | 7351 | 4.04857817 | CS |
| 52 | -3.215 | -51.729686243 | 6.215 | 6.7738 | 3 | 7351 | 4.04857817 | CS |
| 156 | -3.215 | -51.729686243 | 6.215 | 6.7738 | 3 | 7351 | 4.04857817 | CS |
| 260 | -3.215 | -51.729686243 | 6.215 | 6.7738 | 3 | 7351 | 4.04857817 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
